Trial · NCT03850730
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
NCT03850730, Phase 1, Phase 2, Unknown, Cure HHT
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia. Trials, record NCT03850730. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03850730
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
- NCT number
- NCT03850730
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Cure HHT
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Epistaxis
- Interventions
- Pazopanib
- First posted
- 2019-02-22
- Last updated
- 2022-09-08
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent change in epistaxis duration in minutes | Summed minutes of bleeding at baseline 3 weeks and the last 3 weeks of dosing, over16-24 weeks of dosing | A daily electronic record of each bleed, with start and end time, provides the daily epistaxis duration, compounded over each 3 weeks of study time |
| Secondary | Percent change in average gushing frequency | Last 3 weeks of drug period vs baseline 3 weeks; over 16-24 weeks of dosing | Patient rated intensity of each bleed, as in 0 or 1, averaged over 3 wk periods. |
| Secondary | Percent change in average bleed frequency | Last 3 weeks compared to the baseline 3 weeks; over 16-24 weeks of dosing | Annotated number of bleeds per day, and summed over 3 week periods |
| Secondary | Absolute [gm/dl] change in serum hemoglobin | comparing last 6 weeks to baseline 3-6 weeks; over 16-24 weeks of drug dosing | Serum values drawn every 3 weeks |
| Secondary | Change in the frequency of blood transfusions | Final 6 weeks of study, compared to baseline 3-6 weeks; over 16- 24 weeks of dosing | Use of packed red blood cells over 6 week time periods. |
| Secondary | Change in the frequency of IV iron infusions | Last 6 weeks of dosing to first 6 weeks; over 16-24 weeks of drug administration | Number of interval IV iron infusions in 6 week periods |
| Secondary | Percent change in the per bleed average epistaxis severity | The final 3 weeks to the baseline 3 weeks of the study; for a16-24 week duration study | Epistaxis severity score \[0-10\] housed in the current patient reported outcome instrument will be averaged |
| Secondary | Daily monitoring for change in systolic blood pressure [mm mercury] using daily recordings | Daily from baseline through up to 24 weeks till on-drug study completion. | Patients rising above 140 mm mercury, or those who increase by 20 or more mm mercury will trigger protocol defined treatments. |
| Secondary | Daily monitoring for change in diastolic blood pressure [mm mercury] | Daily from baseline through up to 24 weeks till on-drug study completion | Patients rising above 90 mm mercury, or those who increase by 10 mm mercury or more will trigger protocol defined treatments. |
| Secondary | Number of participants with changes in alanine aminotransferase [liver function test] | Baseline and throughout the 16-24 week dosing period | measurement every 3 weeks to evaluate fold increase with use of drug |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03850730
GET https://conductscience.org/api/trials/v1/NCT03850730/registered